9 results about "DIAGNOSTIC ANTIGENS" patented technology

The application discloses a highly immature duck Tembusu virus, a culture method and application thereof, and belongs to the technical field of biotechnology.According to the method for culturing the highly immature duck Tembusu virus based on the LOVO cell line provided in the application, the duck Tembusu virus obtained by culture loses pathogenicity, the application provides a highly potential candidate strain for developing safe and effective duck Tembusu virus vaccines, opens up a new way for safely producing high-quality diagnostic antigens and vaccine antigens, and significantly reduces the biosafety risk of related research.

The invention provides two specific diagnostic antigens for chicken infected with dog head roundworm and an ELISA diagnostic kit thereof, and belongs to the technical field of biological immunodetection, and the two specific diagnostic antigens are a recombinant protein GAPDH3 and a recombinant protein dim-1; the nucleotide sequence of the specific diagnosis antigen gene GAPDH3 is as shown in SEQ ID NO.1, and the amino acid sequence of the specific diagnosis antigen gene GAPDH3 is as shown in SEQ ID NO.3; the nucleotide sequence of the specific diagnosis antigen gene dim-1 is as shown in SEQ ID NO.2, and the amino acid sequence of the specific diagnosis antigen gene dim-1 is as shown in SEQ ID NO.4. The kit is used for detecting the specific antibody of the dog head roundworm in chicken serum, detection signals can be displayed more clearly in the detection process, misjudgment caused by non-specific reaction is reduced, and the detection accuracy and reliability are improved. The condition of the specific antibody of the dog head roundworm in chicken serum can be more accurately judged, and a more reliable basis is provided for diagnosis of chicken infection of the dog head roundworm.

The invention provides a sheep hepatic fascioliasis early specific diagnosis antigen FhCatL6 and a preparation method and application thereof, and relates to the field of immunological detection.The diagnosis antigen FhCatL6 is expressed based on BAA23743-1 gene, the diagnosis antigen FhCatL6 is recombinant protein FhCatL6, the amino acid sequence of the diagnosis antigen FhCatL6 is shown as SEQ ID NO.1, and the amino acid sequence of BAA23743-1 is shown as SEQ ID NO.2; according to the present invention, the sheep hepatic fascioliasis early-stage specific diagnosis antigen FhCatL6 is screened and determined, the antigen is expressed based on the BAA23743-1 gene, and is prepared by carrying out signal peptide cutting and codon optimization on BAA23743-1, such that the hepatic fascioliasis can be accurately identified, confusion with other similar diseases can be avoided, and the accuracy and the reliability of the diagnosis can be improved.

The application provides an ELISA kit for detecting ovine paratuberculosis antibodies and application, relates to the field of biological detection, and the ELISA kit comprises the following components: paratuberculosis mycobacterium specific diagnostic antigen (amino acid sequence as shown in SEQ ID NO:1, nucleotide sequence as shown in SEQ ID NO:2); coating buffer; blocking solution; serum diluent; enzyme-labeled secondary antibody diluent; substrate solution; stop solution; positive control serum and negative control serum; compared with prior art, the kit provided by the application has good specificity and reduces false positive rate; clinical data shows that the positive detection rate of the kit is 43.78%, which is significantly higher than that of imported kits of ID Vet (6.22%) and IDEXX (3.43%), indicating that the kit has higher sensitivity and can detect infected sheep earlier and more accurately.

The application discloses a diagnostic antigen for quantitatively detecting Yersinia pestis antibody. Specifically disclosed is a protein F1B139 with an amino acid sequence of SEQ ID No. 1 and application of the protein F1B139 as an antigen in detection, analysis or evaluation of Yersinia pestis antibody. Experiments show that the Yersinia pestis antigen has good sensitivity, can be recognized by rabbit anti-F1 polyclonal antibody, can be used as a quality control product of a Yersinia pestis antigen detection reagent, ensures batch stability of antibody raw material production, can be used as a raw material of an antibody detection reagent, the recombinant F1 antigen component is single, and the antibody can be accurately evaluated. The immunodetection method and product based on the antigen can realize quantitative detection of the antibody, have good sensitivity, can be widely used in detection, quality control and evaluation of the Yersinia pestis antibody, provide help for clinical diagnosis, curative effect observation, prognosis judgment, epidemiological investigation of infectious diseases and the like, and have very wide clinical application prospects.

The invention relates to the technical field of biological detection, and discloses a GtaA antigen based on a glycosylation modification form and application of the GtaA antigen in aspergillus fumigatus infection detection. The GtaA antigen is exosome glycoprotein from aspergillus, and the amino acid sequence of the GtaA antigen is as shown in SEQ ID NO: 2. The GtaA antigen comprises GtaA which is subjected to full glycosylation, GtaA (N) which is subjected to deglycosylation modification, and GtaA (N-O) which is subjected to non-glycosylation modification. The invention establishes an immunological detection method based on different forms of GtaA antigens. Experiments show that glycosylation modification affects antigen diagnosis performance, but GtaA in glycosylation and non-glycosylation forms can be used as specific diagnosis antigens of aspergillus infection. The invention is widely applicable to rapid detection of aspergillus fungal infection, including immunological detection modes such as enzyme-linked immunosorbent assay, immunochromatography, immunoblotting, chemiluminescence and the like, and has important clinical application potential and popularization value.

The invention relates to the technical field of animal infectious disease diagnosis and vaccines, in particular to a Brucella disease DIVA diagnosis antigen BruAb20955, and the amino acid sequence of the BruAb20955 protein is as shown in SEQ ID NO: 2. A nucleotide sequence for coding the brucellosis DIVA diagnosis antigen is characterized in that the nucleotide sequence is as shown in SEQ ID NO: 1. A primer pair for amplifying the nucleotide sequence is characterized in that an upstream primer sequence is as shown in SEQ ID NO: 3, and a downstream primer sequence is as shown in SEQ ID NO: 4. The invention further discloses application of the nucleotide sequence, the amino acid sequence and the BruAb20955 protein in preparation of a DIVA diagnostic reagent for brucellosis. The invention further discloses application of the nucleotide sequence, the amino acid sequence and the BruAb20955 protein in preparation of brucellosis prevention and control vaccines. According to the invention, a new molecular marker which can be used for differential diagnosis of Brucella wild virus infection and vaccine immunity is screened and identified at home and abroad for the first time, and meanwhile, an indirect ELISA method which can be used for experimental differential diagnosis is established by utilizing the new marker molecule. The judgment critical value of the method is 1.908.

The invention relates to a cat hepatitis virus core antigen virus-like particle as well as a preparation method and application thereof. The virus-like particle is prepared by expressing a wild type gene DCHcWT of a cat hepatitis virus core antigen or a 1-149 amino acid truncated gene DCHcN149 of an amino terminal of the wild type gene DCHcWT in an insect baculovirus expression system, and purifying and self-assembling the wild type gene DCHcWT or the 1-149 amino acid truncated gene DCHcN149 in the insect baculovirus expression system. The prepared virus-like particles are regular in structure and good in immunogenicity, and antigen characteristics of natural virus particles can be efficiently simulated. The virus-like particle can be used as a diagnosis antigen of cat hepatitis B virus infection, and is used for preparing a serum detection kit for cat hepatitis. The vaccine can also be used as an immunogen to prepare a subunit vaccine for preventing cat hepatitis B; the compound can also be used for vaccine nano-delivery carriers.

This invention discloses a fusion protein, PEDV RBD nanoparticle antigen, its preparation method, and its applications. The fusion protein is obtained by fusing the receptor-binding domain of the porcine epidemic diarrhea virus (PEDV) Spike protein to the N-terminus of a ferritin monomer via a linker peptide. It can self-assemble into PEDV RBD nanoparticle antigens with an average diameter of approximately 15 nm. The nanoparticle antigens exhibit structural integrity, enabling high-density multivalent display of the RBD, and possess excellent antigenic activity, specificity, thermal stability, and biocompatibility, making them suitable for large-scale production. This invention provides a safe, infection-free, and easily industrialized vaccine strategy for addressing PEDV infection. It can be further expanded for applications in veterinary vaccine formulation optimization and the research and development of diagnostic antigens and reagents, demonstrating good practicality and industrialization prospects.